Clinical Trial

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

Study acronym: HepaGrowth
Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality. Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-17; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-07-06
Trial Details
NCT Number NCT04762992
Lead Sponsor Centro Hospitalar de Lisboa Central
Collaborators: NOVA Medical School
Conditions Fetal Growth Retardation, Prematurity, Pre-Eclampsia
Enrollment 12 participants
Start Date 2022-07-18
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-13